Overcoming challenges to cellular starting material collection

Coordinating the collection and delivery of cells for cell and gene therapy developers begins long before the first patient or donor is collected. Our Be The Match BioTherapies® Collection Network Liaison team works with cell and gene therapy clients to understand their needs. Then, they use established, standardized approaches to onboard, audit and train the…

Abby McDonald, PhD, is the manager of Solutions Development at Be The Match BioTherapies

Driving CAR-T therapy safety and sustainability for the road ahead

Autologous and allogeneic CAR-T therapies continue to hold significant promise for patients. But with that potential comes challenges, as more CAR-T therapies enter clinical trials and commercialization. Some are universal to both autologous CAR-T and allogeneic CAR-T, but each has its unique obstacles, too. Abby McDonald, PhD, supervises the Solutions Development team for Be The…

Industry stakeholders propose unified CAR T toxicity grading scale

Chimeric antigen receptor (CAR) T cell therapies and other new immune effector cell therapies are offering hope for many patients with relapsed and refractory leukemia, lymphoma and other blood cancers. However, these therapies also have known serious side effects, including cytokine release syndrome (CRS) and immune effector cell neurotoxicity syndrome (ICANS). Because the definitions and…